SO
Nxera Pharma Co., Ltd.
SOLTF · OTC
$7.84 +6.31% (+$0.47)
1M +7.59%
Market Cap ¥103.7B
P/E Ratio -
Div. Yield -
ROE 12.22%
Bulios Fair Price
$10.03
28.0% upside
Current Price
$7.84
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SOLTF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
22 /100
Expensive EV/EBITDA 50.33x
P/S 3.09x
P/B 1.61x
Growth
85 /100
Growing Rev. growth 23.94%
Book val. growth 1.76%
EPS growth N/A
Profitability
23 /100
Weak Gross margin 76.04%
Net margin 23.31%
Op. margin 6.56%
Quality
3 /100
Poor ROIC 1.41%
ROE 12.22%
ROA 5.95%
Debt
33 /100
High Debt/Equity 0.84x
Current ratio 2.66x
Int. coverage -0.24x
Stability
2 /100
Unstable Beta 0.22x
Rev. volatility 77.76%
EPS volatility 1,114.25%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SOLTF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher Cargill
Employees
382
Headquarters
Tokyo
Upcoming events
06 NOV
Earnings
Upcoming earnings report